Modulating SIRT1 activity variously affects thymic lymphoma development in mice. 2018

Katherine V Clark-Knowles, and Danielle Dewar-Darch, and Karen E Jardine, and Josée Coulombe, and Manijeh Daneshmand, and Xiaohong He, and Michael W McBurney
Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Canada. Electronic address: kaclark@ohri.ca.

SIRT1 is a protein deacetylase with a broad range of biological functions, many of which are known to be important in carcinogenesis, however much of the literature regarding the role of SIRT1 in cancer remains conflicting. In this study we assessed the effect of SIRT1 on the initiation and progression of thymic T cell lymphomas. We employed mouse strains in which SIRT1 activity was absent or could be reversibly modulated in conjunction with thymic lymphoma induction using either the N-nitroso-N-methylurea (NMU) carcinogenesis or the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) transgene. Decreased SIRT1 activity reduced the development of thymic lymphomas in the NMU-treated mice but was permissive for the formation of lung adenomas. Conversely, in the NPM-ALK transgenic mice, decreased SIRT1 activity had a modest promoting effect in the development of thymic lymphomas. The results of the work presented here add to the growing body of evidence that sirt1 is neither an outright oncogene nor a tumor suppressor. These opposing results in two models of the same disease suggest that the influence of sirt1 on carcinogenesis may lie in a role in tumor surveillance.

UI MeSH Term Description Entries
D008297 Male Males
D008770 Methylnitrosourea A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties. Nitrosomethylurea,N-Methyl-N-nitrosourea,NSC-23909,N Methyl N nitrosourea,NSC 23909,NSC23909
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009928 Organ Specificity Characteristic restricted to a particular organ of the body, such as a cell type, metabolic response or expression of a particular protein or antigen. Tissue Specificity,Organ Specificities,Specificities, Organ,Specificities, Tissue,Specificity, Organ,Specificity, Tissue,Tissue Specificities
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D000077192 Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer. Lung Adenocarcinoma,Adenocarcinoma, Lung,Adenocarcinomas, Lung,Lung Adenocarcinomas
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013629 Tamoxifen One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM. ICI-46,474,ICI-46474,ICI-47699,Nolvadex,Novaldex,Soltamox,Tamoxifen Citrate,Tomaxithen,Zitazonium,Citrate, Tamoxifen,ICI 46,474,ICI 46474,ICI 47699,ICI46,474,ICI46474,ICI47699

Related Publications

Katherine V Clark-Knowles, and Danielle Dewar-Darch, and Karen E Jardine, and Josée Coulombe, and Manijeh Daneshmand, and Xiaohong He, and Michael W McBurney
September 1985, Journal of the National Cancer Institute,
Katherine V Clark-Knowles, and Danielle Dewar-Darch, and Karen E Jardine, and Josée Coulombe, and Manijeh Daneshmand, and Xiaohong He, and Michael W McBurney
September 2002, Cancer research,
Katherine V Clark-Knowles, and Danielle Dewar-Darch, and Karen E Jardine, and Josée Coulombe, and Manijeh Daneshmand, and Xiaohong He, and Michael W McBurney
April 1967, Journal of the National Cancer Institute,
Katherine V Clark-Knowles, and Danielle Dewar-Darch, and Karen E Jardine, and Josée Coulombe, and Manijeh Daneshmand, and Xiaohong He, and Michael W McBurney
March 1967, International journal of cancer,
Katherine V Clark-Knowles, and Danielle Dewar-Darch, and Karen E Jardine, and Josée Coulombe, and Manijeh Daneshmand, and Xiaohong He, and Michael W McBurney
April 1963, Transactions of the New York Academy of Sciences,
Katherine V Clark-Knowles, and Danielle Dewar-Darch, and Karen E Jardine, and Josée Coulombe, and Manijeh Daneshmand, and Xiaohong He, and Michael W McBurney
February 2003, Oncogene,
Katherine V Clark-Knowles, and Danielle Dewar-Darch, and Karen E Jardine, and Josée Coulombe, and Manijeh Daneshmand, and Xiaohong He, and Michael W McBurney
June 2009, Biochemical and biophysical research communications,
Katherine V Clark-Knowles, and Danielle Dewar-Darch, and Karen E Jardine, and Josée Coulombe, and Manijeh Daneshmand, and Xiaohong He, and Michael W McBurney
January 2003, Oncogene,
Katherine V Clark-Knowles, and Danielle Dewar-Darch, and Karen E Jardine, and Josée Coulombe, and Manijeh Daneshmand, and Xiaohong He, and Michael W McBurney
October 2007, PloS one,
Katherine V Clark-Knowles, and Danielle Dewar-Darch, and Karen E Jardine, and Josée Coulombe, and Manijeh Daneshmand, and Xiaohong He, and Michael W McBurney
November 2023, European journal of immunology,
Copied contents to your clipboard!